Details
Stereochemistry | ACHIRAL |
Molecular Formula | C8H15NO3 |
Molecular Weight | 173.2096 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(=O)NCCCCCC(O)=O
InChI
InChIKey=WDSCBUNMANHPFH-UHFFFAOYSA-N
InChI=1S/C8H15NO3/c1-7(10)9-6-4-2-3-5-8(11)12/h2-6H2,1H3,(H,9,10)(H,11,12)
Molecular Formula | C8H15NO3 |
Molecular Weight | 173.2096 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: https://www.rlsnet.ru/mnn_index_id_1901.htmCurator's Comment: The description was created based on several sources, including
https://www.drugs.com/international/acexamic-acid.html | https://www.ncbi.nlm.nih.gov/pubmed/18353035 | https://www.ncbi.nlm.nih.gov/pubmed/6159453 | https://www.ncbi.nlm.nih.gov/pubmed/19470000
Sources: https://www.rlsnet.ru/mnn_index_id_1901.htm
Curator's Comment: The description was created based on several sources, including
https://www.drugs.com/international/acexamic-acid.html | https://www.ncbi.nlm.nih.gov/pubmed/18353035 | https://www.ncbi.nlm.nih.gov/pubmed/6159453 | https://www.ncbi.nlm.nih.gov/pubmed/19470000
Acexamic acid (N-acetyl-amino-6-hexanoic acid) is a drug used as a cicatrization helper. Some studies show that the acexamic acid prevents the formation the connective inflamed tissue and enables its healing. The association from acexamic acid with zinc, zinc acexamate, has been used in the treatment of gastric and duodenal ulcer and in the prevention of gastric ulcer induced by nonsteroidal anti-inflammatory drugs.
Originator
Approval Year
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | Acemin ointment Approved UseLong-lasting non-healing wounds, skin and mucous burns, chronic traumatic osteomyelitis, closed and long-lasting incomplete fractures of bones, prevention of hyper-scarring, acceleration of the formation of a postoperative cosmetic scar, acceleration of engraftment of auto- and homotransplants. |
|||
Curative | Acemin ointment Approved UseLong-lasting non-healing wounds, skin and mucous burns, chronic traumatic osteomyelitis, closed and long-lasting incomplete fractures of bones, prevention of hyper-scarring, acceleration of the formation of a postoperative cosmetic scar, acceleration of engraftment of auto- and homotransplants. |
PubMed
Title | Date | PubMed |
---|---|---|
Increase in bone growth factors with healing rat fractures: the enhancing effect of zinc. | 2001 Oct |
|
Great increase in bone 66 kDa protein and osteocalcin at later stages with healing rat fractures: effect of zinc treatment. | 2003 Feb |
|
[Nickel and magnesium effects in the rat kidney, treated with acid retinoic. Comparative study]. | 2007 Jul-Sep |
|
Effect of zinc on gene expression in osteoblastic MC3T3-E1 cells: enhancement of Runx2, OPG, and regucalcin mRNA expressions. | 2008 May |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/18353035
Curator's Comment: http://www.lsgeotar.ru/atsexamovaya-kislota.html
Outer: 5% ointment is applied to the disinfected wound surface daily. The course of treatment is from 10 to 30 days.
Route of Administration:
Topical
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/19470000
The mouse fibroblast cell line (NCTC Clone L 929) was maintained as stock culture in a minimum essential medium (MEM) supplemented with 10% calf serum and 200 i.u./ml G penicillin and 100 pg/d streptomycin. Cultures for growth studies were established by inoculating 7 X l0^4 cells in 2 ml medium in 35-mm plastic tissue culture dishes. They were maintained for 24 h to obtain a good attachment, then incubated in 5% calf serum medium supplemented or not with the drugs tested. Acexamic acid increased the growth rate of L 929 when used at a concentration of 0.001%
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 17:50:38 GMT 2023
by
admin
on
Sat Dec 16 17:50:38 GMT 2023
|
Record UNII |
7IC4BO7D3R
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C257
Created by
admin on Sat Dec 16 17:50:39 GMT 2023 , Edited by admin on Sat Dec 16 17:50:39 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
100000084602
Created by
admin on Sat Dec 16 17:50:39 GMT 2023 , Edited by admin on Sat Dec 16 17:50:39 GMT 2023
|
PRIMARY | |||
|
DTXSID1045879
Created by
admin on Sat Dec 16 17:50:39 GMT 2023 , Edited by admin on Sat Dec 16 17:50:39 GMT 2023
|
PRIMARY | |||
|
2005
Created by
admin on Sat Dec 16 17:50:39 GMT 2023 , Edited by admin on Sat Dec 16 17:50:39 GMT 2023
|
PRIMARY | |||
|
CHEMBL2105922
Created by
admin on Sat Dec 16 17:50:39 GMT 2023 , Edited by admin on Sat Dec 16 17:50:39 GMT 2023
|
PRIMARY | |||
|
7IC4BO7D3R
Created by
admin on Sat Dec 16 17:50:39 GMT 2023 , Edited by admin on Sat Dec 16 17:50:39 GMT 2023
|
PRIMARY | |||
|
SUB05234MIG
Created by
admin on Sat Dec 16 17:50:39 GMT 2023 , Edited by admin on Sat Dec 16 17:50:39 GMT 2023
|
PRIMARY | |||
|
15978
Created by
admin on Sat Dec 16 17:50:39 GMT 2023 , Edited by admin on Sat Dec 16 17:50:39 GMT 2023
|
PRIMARY | RxNorm | ||
|
3000
Created by
admin on Sat Dec 16 17:50:39 GMT 2023 , Edited by admin on Sat Dec 16 17:50:39 GMT 2023
|
PRIMARY | |||
|
C018802
Created by
admin on Sat Dec 16 17:50:39 GMT 2023 , Edited by admin on Sat Dec 16 17:50:39 GMT 2023
|
PRIMARY | |||
|
57-08-9
Created by
admin on Sat Dec 16 17:50:39 GMT 2023 , Edited by admin on Sat Dec 16 17:50:39 GMT 2023
|
PRIMARY | |||
|
m1316
Created by
admin on Sat Dec 16 17:50:39 GMT 2023 , Edited by admin on Sat Dec 16 17:50:39 GMT 2023
|
PRIMARY | Merck Index | ||
|
200-310-8
Created by
admin on Sat Dec 16 17:50:39 GMT 2023 , Edited by admin on Sat Dec 16 17:50:39 GMT 2023
|
PRIMARY | |||
|
12945
Created by
admin on Sat Dec 16 17:50:39 GMT 2023 , Edited by admin on Sat Dec 16 17:50:39 GMT 2023
|
PRIMARY | |||
|
C80535
Created by
admin on Sat Dec 16 17:50:39 GMT 2023 , Edited by admin on Sat Dec 16 17:50:39 GMT 2023
|
PRIMARY | |||
|
2246
Created by
admin on Sat Dec 16 17:50:39 GMT 2023 , Edited by admin on Sat Dec 16 17:50:39 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |